A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide) in Children From 6 to Less Than 12 Years of Age With Asthma
Latest Information Update: 14 Sep 2025
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
Most Recent Events
- 03 Jun 2025 Planned End Date changed from 19 Jun 2025 to 30 Aug 2027.
- 03 Jun 2025 Planned primary completion date changed from 10 Jun 2025 to 30 Jul 2027.
- 31 Dec 2024 Planned End Date changed from 10 Jun 2025 to 19 Jun 2025.